Interrupting effect of social distancing on ischemic heart disease, asthma, stroke, and suicide attempt patients by PM(2.5) exposure - Choi M, Son M, Bae S, Lee W, Kim KN, Hyun JK.
This study aimed to examine the interrupting effect of social distancing (SD) on emergency department (ED) patients with ischemic heart disease (IHD), stroke, asthma, and suicide attempts by PM(2.5) exposure in eight Korean megacities from 2017 to... (Source: SafetyLit)
Source: SafetyLit - April 25, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Heart Failure, Not Stroke, Most Common Complication of A-Fib Heart Failure, Not Stroke, Most Common Complication of A-Fib
A new study found the lifetime risks of post-AF stroke, ischemic stroke, and myocardial infarction improved remained high, with virtually no improvement in the lifetime risk for heart failure.MDedge News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 22, 2024 Category: Cardiology Tags: Internal Medicine News Source Type: news
Can ChatGPT ‘data mine’ patient reports for stroke registries?
ChatGPT-4 appears useful for extracting details from reports on thrombectomy procedures in stroke patients, a labor-intensive and error-prone task currently performed by human readers, according to a group in Germany.
Such “data mining” by ChatGPT could provide an alternative to manual methods for building stroke registries, with the data being key to improving the quality of stroke care, noted lead author Nils Lehnen, MD, of University Hospital Bonn, and colleagues.
“Procedural details of mechanical thrombectomy in patients with ischemic stroke are predictors of clinical outcome and are collected for prospective s...
Source: AuntMinnie.com Headlines - April 19, 2024 Category: Radiology Authors: Will Morton Tags: Digital X-Ray Interventional Artificial Intelligence Source Type: news
Roche ’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III...
Source: Roche Media News - April 17, 2024 Category: Pharmaceuticals Source Type: news
Can brain MRI for emergency imaging of dizziness be more effective?
Predictors for acute conditions such as stroke could make brain MRI a better choice in patients who present in the emergency department with dizziness or vertigo, according to research published April 11 in the American Journal of Neuroradiology.
A team led by Tatu Happonen, MD, of the University of Turku in Finland found that factors such as older age, male sex, cardiovascular risk level, and particular neurologic signs appear to help clinicians better determine whether a patient could benefit from MR imaging -- thus reducing unnecessary exams.
"Acute dizziness and vertigo remain challenging even when emergency MR imagi...
Source: AuntMinnie.com Headlines - April 15, 2024 Category: Radiology Authors: Kate Madden Yee Tags: MRI Neuroradiology Source Type: news
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. T...
Source: Roche Investor Update - April 7, 2024 Category: Pharmaceuticals Source Type: news
COVID-19 ‘Radically’ Changed the Leading Causes of Death
COVID-19 became the second leading cause of death globally in the year after it was declared a pandemic, according to a study published in the Lancet.
While heart disease remained the top killer, COVID “radically altered” the main five causes of death for the first time in 30 years, displacing stroke, the publication said. In 2021, 94 in every 100,000 people died from COVID, on an age-standardized basis.
Since 1990, global life expectancy increased by 6.2 years, mainly due to reductions in death from diarrhea and lower respiratory infections and better outcomes for people suffering from a stroke or ischem...
Source: TIME: Health - April 5, 2024 Category: Consumer Health News Authors: Alex Tanzi/Bloomberg Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
Reducing Alcohol Intake Tied to Fewer CV Events Reducing Alcohol Intake Tied to Fewer CV Events
The benefits of changing drinking behavior among those with higher intakes were due mainly to significant reductions in angina and ischemic stroke.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 29, 2024 Category: Cardiology Tags: Cardiology Source Type: news
DAPT Maintains Early Neurologic Function in Mild-Moderate Stroke
(MedPage Today) -- In certain patients with mild-to-moderate acute ischemic stroke, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel (Plavix) reduced early neurologic deterioration better than aspirin alone, the Chinese randomized... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 13, 2024 Category: Cardiology Source Type: news
Most Disadvantaged Least Likely to Receive Thrombolysis Most Disadvantaged Least Likely to Receive Thrombolysis
Black, male, and older ischemic stroke patients are less likely than other populations to antithrombolytic therapy.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 8, 2024 Category: Neurology Tags: Neurology & Neurosurgery Source Type: news
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Investor Update - March 5, 2024 Category: Pharmaceuticals Source Type: news
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Media News - March 5, 2024 Category: Pharmaceuticals Source Type: news
Hourly Heat Exposure Linked to Increased Risk for Acute Ischemic Stroke
THURSDAY, Feb. 29, 2024 -- Hourly heat exposure is associated with an increased risk for acute ischemic stroke (AIS) onset, according to a study published online Feb. 28 in JAMA Network Open.
Xinlei Zhu, from Fudan University in Shanghai, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 29, 2024 Category: Pharmaceuticals Source Type: news
Anti-cancer drug could improve symptoms after stroke
A study by the Institut de Neurociències of the UAB (INc-UAB) demonstrates in animal models the benefits of vorinostat after having suffered a stroke. The drug, used in humans to treat cutaneous T-cell lymphoma, has been proved to mitigate brain injuries and help in restoring brain tissue.
Ischemic stroke is the second leading cause of death worldwide and occurs when blood flow cannot reach the brain due to an obstruction. (Source: World Pharma News)
Source: World Pharma News - February 28, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Thrombectomy Benefits Large Core Stroke Out to 1 Year Thrombectomy Benefits Large Core Stroke Out to 1 Year
New results from the SELECT2 trial also show benefit of the procedure in a large range of ischemic core sizes and in patients transferred from an outside hospital.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 22, 2024 Category: Cardiology Tags: Cardiology Source Type: news
